Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Introduction: In the 20 years since its introduction to the palette of intravenous hemodynamic therapies, the inodilator levosimendan has established itself as a valuable asset for the management of acute decompensated heart failure. Its pharmacology is notable for delivering inotropy via calcium sensitization without an increase in myocardial oxygen consumption.Areas covered: Experience with levosimendan has led to its applications expanding into perioperative hemodynamic support and various critical care settings, as well as an array of situations associated with acutely decompensated heart failure, such as right ventricular failure, cardiogenic shock with multi-organ dysfunction, and cardio-renal syndrome. Evidence suggests that levosimendan may be preferable to milrinone for patients in cardiogenic shock after cardiac surgery or for weaning from extracorporeal life support and may be superior to dobutamine in terms of short-term survival, especially in patients on beta-blockers. Positive effects on kidney function have been noted, further differentiating levosimendan from catecholamines and phosphodiesterase inhibitors.Expert opinion:Levosimendan can be a valuable resource in the treatment of acute cardiac dysfunction, especially in the presence of beta-blockers or ischemic cardiomyopathy. When attention is given to avoiding or correcting hypovolemia and hypokalemia, an early use of the drug in the treatment algorithm is preferred.

Citation

Matthias Heringlake, Julian Alvarez, Dominique Bettex, Stefaan Bouchez, Sonja Fruhwald, Massimo Girardis, Elena Grossini, Fabio Guarracino, Antoine Herpain, Wolfgang Toller, Luigi Tritapepe, Piero Pollesello. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert review of cardiovascular therapy. 2021 Apr;19(4):325-335

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33739204

View Full Text